Update on Recommendations for the Clinical Management of Hepatitis C in Iran 2017

Authors Information
Article Notes and Dates
To Cite : Alavian S M, Sharafi H. Update on Recommendations for the Clinical Management of Hepatitis C in Iran 2017, Hepat Mon. 2017 ;17(11):e63956. doi: 10.5812/hepatmon.63956.
Copyright: Copyright © 2017, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Update on Treatment of HCV Genotype 1 and 4 Infections
3. Update on Treatment of HCV Genotype 3 Infection
4. Is it Important to Genotype HCV Prior to Treatment?
5. Update on Treatment of HCV in Patients with Chronic Renal Failure
Footnotes
References
  • 1. Hesamizadeh K, Sharafi H, Rezaee-Zavareh MS, Behnava B, Alavian SM. Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals. Hepat Mon. 2016; 16(4): 37089[DOI][PubMed]
  • 2. Rezaee-Zavareh MS, Hesamizadeh K, Behnava B, Alavian SM, Gholami-Fesharaki M, Sharafi H. Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis. Ann Hepatol. 2017; 16(2): 188-97[DOI][PubMed]
  • 3. Dolatimehr F, Karimi-Sari H, Rezaee-Zavareh MS, Alavian SM, Behnava B, Gholami-Fesharaki M, et al. Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis. Daru. 2017; 25(1): 11[DOI][PubMed]
  • 4. Rezaee-Zavareh MS, Hesamizadeh K, Sharafi H, Alavian SM. Treatment of hepatitis c infection with direct-acting antiviral agents in liver-transplant patients: A systematic review and meta-analysis. Hepat Mon. 2017; 17(6)
  • 5. Sharafi H, Nikbin M, Alavian SH, Behnava B, Alavian SM. Efficacy and safety of generic sofosbuvir/ledipasvir fixed-dose combination in iranian patients with chronic hepatitis C virus infection. Hepat Mon. 2017; 17(6)[DOI]
  • 6. Merat S, Sharifi AH, Haj-Sheykholeslami A, Poustchi H, Fattahi B, Nateghi-Baygi A. The efficacy of 12 weeks of sofosbuvir, daclatasvir, and ribavirin in treating hepatitis c patients with cirrhosis, genotypes 1 and 3. Hepat Mon. 2017; 17(1): 44564
  • 7. Hajarizadeh B. Generic direct acting antiviral treatment: The first step towards elimination of hepatitis C in Iran. Hepat Mon. 2017; 17(1): 45788
  • 8. Hajarizadeh B, Razavi-Shearer D, Merat S, Alavian SM, Malekzadeh R, Razavi H. Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden. Hepat Mon. 2016; 16(7): 37234[DOI][PubMed]
  • 9. Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, et al. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepat Mon. 2016; 16(8): 40959[DOI][PubMed]
  • 10. Curry MP, Tapper EB, Bacon B, Dieterich D, Flamm SL, Guest L, et al. Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naive, genotype 1 hepatitis C infected patients. Aliment Pharmacol Ther. 2017; 46(5): 540-8[DOI][PubMed]
  • 11. Alavian SM, Rezaee-Zavareh MS. Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis. Hepat Mon. 2016; 16(9): 41077[DOI][PubMed]
  • 12. Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015; 373(27): 2599-607[DOI][PubMed]
  • 13. Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015; 373(27): 2618-28[DOI][PubMed]
  • 14. Gane EJ, Shiffman ML, Etzkorn K, Morelli G, Stedman CAM, Davis MN, et al. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen. Hepatology. 2017; 66(4): 1083-9[DOI][PubMed]
  • 15. Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015; 373(27): 2608-17[DOI][PubMed]
  • 16. Zanaga LP, Miotto N, Mendes LC, Stucchi RS, Vigani AG. Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents. Braz J Med Biol Res. 2016; 49(11): 5504
  • 17. Keshvari M, Alavian SM, Behnava B, Pouryasin A, Craig JC, Sharafi H. Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-alpha and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C. J Clin Lab Anal. 2017; 31(4)[DOI][PubMed]
  • 18. Behnava B, Sharafi H, Keshvari M, Pouryasin A, Mehrnoush L, Salimi S, et al. The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C. Hepat Mon. 2016; 16(1): 32703[DOI][PubMed]
  • 19. Alavian SM, Hepatitis C. Chronic renal failure, control is possible. Hepat Mon. 2006; 6(2): 51-552
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check